- Title
- Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial
- Creator
- Siva, Shankar; Bressel, Mathias; Lin, Charles; Raman, Avi; Hardcastle, Nicholas; Hofman, Michael S.; De Abreu Lourenco, Richard; Shaw, Mark; Mancuso, Pascal; Moon, Daniel; Wong, Lih-Ming; Lawrentschuk, Nathan; Sidhom, Mark; Wood, S; Brook, NR; Kron, T; Martin, Jarad; Pryor, D; FASTRACK II Investigator Group,; Sridharan, Swetha; Vanneste, Ben G. L.; Davey, Ryan; Montgomery, Rebecca; Ruben, Jeremy; Foroudi, Farshad; Higgs, Braden
- Relation
- Lancet Oncology Vol. 25, Issue 3, p. 308-316
- Publisher Link
- http://dx.doi.org/10.1016/S1470-2045(24)00020-2
- Publisher
- The Lancet Publishing Group
- Resource Type
- journal article
- Date
- 2024
- Description
- Background: Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cell cancer who do not undergo surgical resection. The FASTRACK II clinical trial investigated the efficacy of SABR for primary renal cell cancer in a phase 2 trial. Methods: This international, non-randomised, phase 2 study was conducted in seven centres in Australia and one centre in the Netherlands. Eligible patients aged 18 years or older had biopsy-confirmed diagnosis of primary renal cell cancer, with only a single lesion; were medically inoperable, were at high risk of complications from surgery, or declined surgery; and had an Eastern Cooperative Oncology Group performance status of 0–2. A multidisciplinary decision that active treatment was warranted was required. Key exclusion criteria were a pre-treatment estimated glomerular filtration rate of less than 30 mL/min per 1·73 m2, previous systemic therapies for renal cell cancer, previous high-dose radiotherapy to an overlapping region, tumours larger than 10 cm, and direct contact of the renal cell cancer with the bowel. Patients received either a single fraction SABR of 26 Gy for tumours 4 cm or less in maximum diameter, or 42 Gy in three fractions for tumours more than 4 cm to 10 cm in maximum diameter. The primary endpoint was local control, defined as no progression of the primary renal cell cancer, as evaluated by the investigator per Response Evaluation Criteria in Solid Tumours (version 1.1). Assuming a 1-year local control of 90%, the null hypothesis of 80% or less was considered not to be worthy of proceeding to a future randomised controlled trial. All patients who commenced trial treatment were included in the primary outcome analysis. This trial is registered with ClinicalTrials.gov, NCT02613819, and has completed accrual. Findings: Between July 28, 2016, and Feb 27, 2020, 70 patients were enrolled and initiated treatment. Median age was 77 years (IQR 70–82). Before enrolment, 49 (70%) of 70 patients had documented serial growth on initial surveillance imaging. 49 (70%) of 70 patients were male and 21 (30%) were female. Median tumour size was 4·6 cm (IQR 3·7–5·5). All patients enrolled had T1–T2a and N0–N1 disease. 23 patients received single-fraction SABR of 26 Gy and 47 received 42 Gy in three fractions. Median follow-up was 43 months (IQR 38–60). Local control at 12 months from treatment commencement was 100% (p<0·0001). Seven (10%) patients had grade 3 treatment-related adverse events, with no grade 4 adverse events observed. Grade 3 treatment-related adverse events were nausea and vomiting (three [4%] patients), abdominal, flank, or tumour pain (four [6%]), colonic obstruction (two [3%]), and diarrhoea (one [1%]). No treatment-related or cancer-related deaths occurred. Interpretation: To our knowledge, this is the first multicentre prospective clinical trial of non-surgical definitive therapy in patients with primary renal cell cancer. In a cohort with predominantly T1b or larger disease, SABR was an effective treatment strategy with no observed local failures or cancer-related deaths. We observed an acceptable side-effect profile and renal function after SABR. These outcomes support the design of a future randomised trial of SABR versus surgery for primary renal cell cancer. Funding: Cancer Australia Priority-driven Collaborative Cancer Research Scheme.
- Subject
- renal cell cancer; clinical trial; biopsy-confirmed diagnosis; phase 2 clinical trial
- Identifier
- http://hdl.handle.net/1959.13/1500715
- Identifier
- uon:54994
- Identifier
- ISSN:1470-2045
- Language
- eng
- Reviewed
- Hits: 4239
- Visitors: 4230
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|